Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 697 to 700 of 700 entries
Sorted by: Best Match Show Resources per page
Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.

International journal of clinical oncology

Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N.
PMID: 33656656
Int J Clin Oncol. 2021 May;26(5):951-953. doi: 10.1007/s10147-021-01880-5.

No abstract available.

Cite
Otsuka T, Shirakawa T, Shimokawa M, et al. Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. Int J Clin Oncol. 2021;26(5):951-953doi: 10.1007/s10147-021-01880-5.
Otsuka, T., Shirakawa, T., Shimokawa, M., Koga, F., Kawaguchi, Y., Ueda, Y., Nakazawa, J., Komori, A., Otsu, S., Arima, S., Fukahori, M., Okabe, Y., Makiyama, A., Taguchi, H., Honda, T., Shibuki, T., Nio, K., Ide, Y., Mizuta, T., Mitsugi, K., & Ureshino, N. (2021). Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. International journal of clinical oncology, 26(5), 951-953. https://doi.org/10.1007/s10147-021-01880-5
Otsuka, Taiga, et al. "Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study." International journal of clinical oncology vol. 26,5 (2021): 951-953. doi: https://doi.org/10.1007/s10147-021-01880-5
Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N. Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. Int J Clin Oncol. 2021 May;26(5):951-953. doi: 10.1007/s10147-021-01880-5. PMID: 33656656.
Copy Download .nbib Format: NLM
Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.

BMC cancer

Oki E, Shinto E, Shimokawa M, Yamaguchi S, Ishiguro M, Hasegawa S, Takii Y, Ishida H, Kusumoto T, Morita M, Tomita N, Shiozawa M, Tanaka M, Ozawa H, Hashiguchi Y, Ohnuma S, Tada S, Matsushima T, Hase K.
PMID: 34906120
BMC Cancer. 2021 Dec 14;21(1):1332. doi: 10.1186/s12885-021-09088-6.

BACKGROUND: Adjuvant chemotherapy reduces the risk of recurrence of stage III colon cancer (CC). However, more effective prognostic and predictive biomarkers are needed for better treatment stratification of affected patients. Here, we constructed a 55-gene classifier (55GC) and investigated...

Cite
Oki E, Shinto E, Shimokawa M, et al. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients. BMC Cancer. 2021;21(1):1332doi: 10.1186/s12885-021-09088-6.
Oki, E., Shinto, E., Shimokawa, M., Yamaguchi, S., Ishiguro, M., Hasegawa, S., Takii, Y., Ishida, H., Kusumoto, T., Morita, M., Tomita, N., Shiozawa, M., Tanaka, M., Ozawa, H., Hashiguchi, Y., Ohnuma, S., Tada, S., Matsushima, T., & Hase, K. (2021). Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients. BMC cancer, 21(1), 1332. https://doi.org/10.1186/s12885-021-09088-6
Oki, Eiji, et al. "Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients." BMC cancer vol. 21,1 (2021): 1332. doi: https://doi.org/10.1186/s12885-021-09088-6
Oki E, Shinto E, Shimokawa M, Yamaguchi S, Ishiguro M, Hasegawa S, Takii Y, Ishida H, Kusumoto T, Morita M, Tomita N, Shiozawa M, Tanaka M, Ozawa H, Hashiguchi Y, Ohnuma S, Tada S, Matsushima T, Hase K. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients. BMC Cancer. 2021 Dec 14;21(1):1332. doi: 10.1186/s12885-021-09088-6. PMID: 34906120; PMCID: PMC8672629.
Copy Download .nbib Format: NLM
The Glasgow Prognostic Score Before Curative Resection May Predict Postoperative Complications in Patients with Gastric Cancer.

Journal of gastrointestinal cancer

Shimoda Y, Fujikawa H, Komori K, Watanabe H, Takahashi K, Kano K, Yamada T, Shiozawa M, Morinaga S, Katsumata K, Tsuchida A, Ogata T, Oshima T.
PMID: 34519976
J Gastrointest Cancer. 2021 Sep 14; doi: 10.1007/s12029-021-00689-9. Epub 2021 Sep 14.

PURPOSE: Despite improvements in surgical techniques and devices and perioperative care of gastric cancer (GC), the rate of postoperative complications still has not decreased. If patients at high risk for postoperative complications could be identified early using biomarkers, these...

Cite
Shimoda Y, Fujikawa H, Komori K, et al. The Glasgow Prognostic Score Before Curative Resection May Predict Postoperative Complications in Patients with Gastric Cancer. J Gastrointest Cancer. 2021;doi: 10.1007/s12029-021-00689-9.
Shimoda, Y., Fujikawa, H., Komori, K., Watanabe, H., Takahashi, K., Kano, K., Yamada, T., Shiozawa, M., Morinaga, S., Katsumata, K., Tsuchida, A., Ogata, T., & Oshima, T. (2021). The Glasgow Prognostic Score Before Curative Resection May Predict Postoperative Complications in Patients with Gastric Cancer. Journal of gastrointestinal cancer, . https://doi.org/10.1007/s12029-021-00689-9
Shimoda, Yota, et al. "The Glasgow Prognostic Score Before Curative Resection May Predict Postoperative Complications in Patients with Gastric Cancer." Journal of gastrointestinal cancer vol. (2021). doi: https://doi.org/10.1007/s12029-021-00689-9
Shimoda Y, Fujikawa H, Komori K, Watanabe H, Takahashi K, Kano K, Yamada T, Shiozawa M, Morinaga S, Katsumata K, Tsuchida A, Ogata T, Oshima T. The Glasgow Prognostic Score Before Curative Resection May Predict Postoperative Complications in Patients with Gastric Cancer. J Gastrointest Cancer. 2021 Sep 14; doi: 10.1007/s12029-021-00689-9. Epub 2021 Sep 14. PMID: 34519976.
Copy Download .nbib Format: NLM
Signet-ring Cell Carcinoma Component as an Indicator of Anaplastic Lymphoma Kinase Mutations in Colorectal Cancer.

Journal of the anus, rectum and colon

Nukada S, Okubo Y, Shiozawa M, Yoshioka E, Suzuki M, Washimi K, Kawachi K, Sato S, Hiroshima Y, Rino Y, Yokose T, Masuda M.
PMID: 33937557
J Anus Rectum Colon. 2021 Apr 28;5(2):167-172. doi: 10.23922/jarc.2020-068. eCollection 2021.

OBJECTIVES: Molecular profiling of marker mutations has become an essential aspect in the treatment planning for colorectal cancer (CRC). Anaplastic lymphoma kinase (METHODS: We screened cases of patients who underwent CRC surgical resection at the Department of Gastrointestinal Surgery...

Cite
Nukada S, Okubo Y, Shiozawa M, et al. Signet-ring Cell Carcinoma Component as an Indicator of Anaplastic Lymphoma Kinase Mutations in Colorectal Cancer. J Anus Rectum Colon. 2021;5(2):167-172doi: 10.23922/jarc.2020-068.
Nukada, S., Okubo, Y., Shiozawa, M., Yoshioka, E., Suzuki, M., Washimi, K., Kawachi, K., Sato, S., Hiroshima, Y., Rino, Y., Yokose, T., & Masuda, M. (2021). Signet-ring Cell Carcinoma Component as an Indicator of Anaplastic Lymphoma Kinase Mutations in Colorectal Cancer. Journal of the anus, rectum and colon, 5(2), 167-172. https://doi.org/10.23922/jarc.2020-068
Nukada, Suguru, et al. "Signet-ring Cell Carcinoma Component as an Indicator of Anaplastic Lymphoma Kinase Mutations in Colorectal Cancer." Journal of the anus, rectum and colon vol. 5,2 (2021): 167-172. doi: https://doi.org/10.23922/jarc.2020-068
Nukada S, Okubo Y, Shiozawa M, Yoshioka E, Suzuki M, Washimi K, Kawachi K, Sato S, Hiroshima Y, Rino Y, Yokose T, Masuda M. Signet-ring Cell Carcinoma Component as an Indicator of Anaplastic Lymphoma Kinase Mutations in Colorectal Cancer. J Anus Rectum Colon. 2021 Apr 28;5(2):167-172. doi: 10.23922/jarc.2020-068. eCollection 2021. PMID: 33937557; PMCID: PMC8084530.
Copy Download .nbib Format: NLM
Showing 697 to 700 of 700 entries